New metabolites of fenofibrate in Sprague–Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS

References

• Blane GF. 1987. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 83(5B):26–36.
   PubMedGoogle Scholar
• Bocher V, Chinetti G, Fruchart JC, Staels B. 2002. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control]. J Soc Biol 196(1):47–52.
   PubMedGoogle Scholar
• Brunmair B, Lest A, Staniek K, Gras F, Scharf N, Roden M, Nohl H, Waldhausl W, Furnsinn C. 2004. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 311(1):109–114.
   PubMedGoogle Scholar
• Cayen MN, Ferdinandi ES, Greselin E, Robinson WT, Dvornik D. 1977. Clofibrate and clofibric acid: comparison of the metabolic disposition in rats and dogs. J Pharmacol Exp Ther 200(1):33–43.
   PubMedGoogle Scholar
• Chen C, Gonzalez FJ, Idle JR. 2007. LC-MS-based metabolomics in drug metabolism. Drug Metab Rev 39(2–3):581–597.
   PubMedGoogle Scholar
• Cornu-Chagnon MC, Dupont H, Edgar A. 1995. Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam Appl Toxicol 26(1):63–74.
   PubMedGoogle Scholar
• Emudianughe TS, Caldwell J, Sinclair KA, Smith RL. 1983. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man. Drug Metab Disposit Biol Fate Chem 11(2):97–102.
   PubMedGoogle Scholar
• Fruchart JC, Duriez P. 2006. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42(1):39–64.
   PubMed Web of Science ®Google Scholar
• Ghosh B, Sengupta S, Bhattacharjee B, Majumder A, Sarkar SB. 2004. Fenofibrate-induced myopathy. Neurol India 52(2):268–269.
   PubMedGoogle Scholar
• Gonzalez FJ, Shah YA. 2008. PPAR alpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246(1):2–8.
   PubMedGoogle Scholar
• Hoivik DJ, Qualls CW Jr, Mirabile RC, Cariello NF, Kimbrough CL, Colton HM, Anderson SP, Santostefano MJ, Morgan RJ, Dahl RR et al. 2004. Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys. Carcinogenesis 25(9):1757–1769.
   PubMedGoogle Scholar
• Holoshitz N, Alsheikh-Ali AA, Karas RH. 2008. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am J Cardiol 101(1):95–97.
   PubMedGoogle Scholar
• Johnson TE, Zhang X, Shi S, Umbenhauer DR. 2005. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol Appl Pharmacol 208(3):210–221.
   PubMedGoogle Scholar
• Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM et al. 2003. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit Rev Toxicol 33(6):655–780.
   PubMedGoogle Scholar
• Lenz EM, Williams RE, Sidaway J, Smith BW, Plumb RS, Johnson KA, Rainville P, Shockcor J, Stumpf CL, Granger JH et al. 2007. The application of microbore UPLC/oa-TOF-MS and 1H-NMR spectroscopy to the metabonomic analysis of rat urine following the intravenous administration of pravastatin. J Pharmaceut Biomed Anal 44(4):845–852.
   PubMedGoogle Scholar
• Lindon JC, Holmes E, Nicholson JK. 2004. Metabonomics: systems biology in pharmaceutical research and development. Curr Opin Mol Ther 6(3):265–272.
   PubMedGoogle Scholar
• Nicholson JK, Lindon JC, Holmes E. 1999. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29(11):1181–1189.
   PubMed Web of Science ®Google Scholar
• Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG. 2000. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. Carcinogenesis 21(4):823–826.
   PubMedGoogle Scholar
• Qu S, Su D, Altomonte J, Kamagate A, He J, Perdomo G, Tse T, Jiang Y, Dong HH. 2007. PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1. Am J Physiol 292(2):E421–E434.
   Google Scholar
• Rao MS, Reddy JK. 1987. Peroxisome proliferation and hepatocarcinogenesis. Carcinogenesis 8(5):631–636.
   PubMedGoogle Scholar
• Reddy JK, Azarnoff DL, Hignite CE. 1980. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283(5745):397–398.
   PubMedGoogle Scholar
• Ritter JL, Nabulsi S. 2001. Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy 21(9):1145–1149.
   PubMedGoogle Scholar
• Ward JM, Peters JM, Perella CM, Gonzalez FJ. 1998. Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice. Toxicol Pathol 26(2):240–246.
   PubMedGoogle Scholar
• Weckwerth W, Morgenthal K. 2005. Metabolomics: from pattern recognition to biological interpretation. Drug Disc Today 10(22):1551–1558.
   PubMedGoogle Scholar
• Weil A, Caldwell J, Strolin-Benedetti M. 1988. The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab Disp Biol Fate Chem 16(2):302–309.
   PubMed Web of Science ®Google Scholar
• Weil A, Caldwell J, Strolin-Benedetti M. 1990. The metabolism and disposition of 14C-fenofibrate in human volunteers. Drug Metab Disp Biol Fate Chem 18(1):115–120.
   PubMedGoogle Scholar
• Yang Q, Ito S, Gonzalez FJ. 2007. Hepatocyte-restricted constitutive activation of PPAR alpha induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis 28(6):1171–1177.
   PubMedGoogle Scholar
• Zhen Y, Krausz KW, Chen C, Idle JR, Gonzalez FJ. 2007. Metabo-lomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Mol Endocrinol (Balt) 21(9):2136–2151.
   PubMedGoogle Scholar